Edition:
India

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

228.97USD
21 Oct 2020
Change (% chg)

$0.00 (+0.00%)
Prev Close
$228.97
Open
--
Day's High
--
Day's Low
--
Volume
1
Avg. Vol
1,178,106
52-wk High
$264.97
52-wk Low
$177.05

Latest Key Developments (Source: Significant Developments)

Amgen Says Positive Data From Phase 3B Study Of Repatha® (Evolocumab) In Pediatric Patients With Heterozygous Familial Hypercholesterolemia
Saturday, 29 Aug 2020 

Aug 29 (Reuters) - Amgen Inc ::AMGEN ANNOUNCES POSITIVE DATA FROM PHASE 3B STUDY OF REPATHA® (EVOLOCUMAB) IN PEDIATRIC PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AT ESC CONGRESS 2020.AMGEN INC - FIRST PHASE 3 TRIAL EVALUATING A PCSK9 INHIBITOR WHEN ADDED TO LIPID-LOWERING THERAPY IN PEDIATRIC HEFH POPULAT.AMGEN INC - REPATHA SIGNIFICANTLY REDUCED LDL-C AND IMPROVED ALL SECONDARY LIPID PARAMETERS.AMGEN INC - NO NEW SAFETY RISKS WERE IDENTIFIED.AMGEN -STUDY SHOW IN PEDIATRIC PATIENTS WITH HEFH, MONTHLY TREATMENT WITH REPATHA REDUCED LDL-C BY MEAN 38.3% FROM BASELINE COMPARED TO PLACEBO.  Full Article

Ligand Announces Amgen’S Kyprolis Approved By FDA To Treat Multiple Myeloma
Monday, 24 Aug 2020 

Aug 24 (Reuters) - Ligand Pharmaceuticals Inc ::LIGAND ANNOUNCES AMGEN’S KYPROLIS® APPROVED BY FDA AS COMBINATION REGIMEN WITH DARZALEX® AND DEXAMETHASONE IN ONCE- AND TWICE-WEEKLY DOSING REGIMENS FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA.LIGAND PHARMACEUTICALS - AMGEN HAS SUBMITTED ADDITIONAL MARKETING APPLICATIONS GLOBALLY FOR KYPROLIS.  Full Article

Amgen Says FDA Approves New Kyprolis Combination Regimen With Darzalex And Dexamethasone In Both Once- And Twice-Weekly Dosing Regimens
Friday, 21 Aug 2020 

Aug 20 (Reuters) - Amgen Inc ::FDA APPROVES NEW KYPROLIS® (CARFILZOMIB) COMBINATION REGIMEN WITH DARZALEX® (DARATUMUMAB) AND DEXAMETHASONE IN BOTH ONCE- AND TWICE-WEEKLY DOSING REGIMENS.AMGEN INC - APPROVAL BASED ON CANDOR AND EQUULEUS STUDIES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA.  Full Article

Arrowhead Pharma Earns $20 Mln Payment From Amgen For Start Of Trial Of AMG 890
Wednesday, 29 Jul 2020 

July 29 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD PHARMACEUTICALS EARNS $20 MILLION MILESTONE PAYMENT FROM AMGEN FOR START OF PHASE 2 TRIAL OF AMG 890.ARROWHEAD PHARMACEUTICALS - EARNED $20 MILLION MILESTONE PAYMENT FROM AMGEN FOLLOWING ADMINISTRATION OF FIRST DOSE OF AMG 890 IN PHASE 2 CLINICAL STUDY.  Full Article

Amgen Announces 2020 Third Quarter Dividend
Friday, 24 Jul 2020 

July 23 (Reuters) - Amgen Inc ::AMGEN ANNOUNCES 2020 THIRD QUARTER DIVIDEND.SETS QUARTERLY DIVIDEND OF $1.60PER SHARE.  Full Article

Moderna Appoints David Meline As Chief Financial Officer
Thursday, 4 Jun 2020 

June 4 (Reuters) - Moderna Inc ::DAVID MELINE JOINS MODERNA AS CHIEF FINANCIAL OFFICER.MODERNA INC - MELINE JOINS MODERNA FROM AMGEN.MODERNA INC - MELINE SERVED AS AMGEN CFO AND EVP FROM 2014 THROUGH 2019.  Full Article

FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure
Friday, 8 May 2020 

May 8 (Reuters) - Amgen Inc ::FDA GRANTS FAST TRACK DESIGNATION FOR OMECAMTIV MECARBIL IN HEART FAILURE.AMGEN - TOP-LINE RESULTS FROM GALACTIC-HF ARE EXPECTED IN Q4 2020.  Full Article

Amgen Announces Positive Top-Line Results From Otezla® Phase 3 Advance Study In Mild-To-Moderate Plaque Psoriasis
Wednesday, 6 May 2020 

May 6 (Reuters) - Amgen Inc ::AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM OTEZLA® (APREMILAST) PHASE 3 ADVANCE STUDY IN MILD-TO-MODERATE PLAQUE PSORIASIS.AMGEN INC - STUDY SHOWED THAT ORAL OTEZLA 30 MG TWICE DAILY ACHIEVED A STATISTICALLY SIGNIFICANT IMPROVEMENT, COMPARED WITH PLACEBO.AMGEN INC - ADVERSE EVENTS OBSERVED IN THIS TRIAL WERE CONSISTENT WITH KNOWN SAFETY PROFILE OF OTEZLA.AMGEN INC - OTEZLA TREATMENT RESULTED IN SIGNIFICANT IMPROVEMENTS IN MEASURES OF MILD-TO-MODERATE PSORIASIS COMPARED WITH PLACEBO.  Full Article

Amgen Inc Says Kyprolis Patents Upheld Against Generic Manufacturer
Tuesday, 5 May 2020 

May 5 (Reuters) - Amgen Inc ::AMGEN INC - KYPROLIS (CARFILZOMIB) PATENTS UPHELD AGAINST GENERIC MANUFACTURER.AMGEN - DECISION WILL PREVENT CIPLA FROM MAKING, USING, SELLING OR IMPORTING GENERIC VERSION OF KYPROLIS UNTIL EXPIRATION OF PATENTS.  Full Article

Amgen Establishes Wholly-Owned Affiliate In Japan
Wednesday, 1 Apr 2020 

March 31 (Reuters) - Amgen Inc ::AMGEN ESTABLISHES WHOLLY-OWNED AFFILIATE IN JAPAN.CONSUMMATED PURCHASE FROM ASTELLAS OF 49% OF SHARES OF AMGEN ASTELLAS BIOPHARMA K.K., JOINT VENTURE BETWEEN CO AND ASTELLAS.  Full Article

Photo

Eli Lilly in deal to supply COVID-19 drugs to low-income countries

Eli Lilly and Co said on Thursday it had entered into an agreement with the Bill & Melinda Gates Foundation for potential supply of its experimental antibody treatments for COVID-19 to low and middle-income countries.